TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02954601

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ORMD-0801 (qd)
Description: Dose 1 = ORMD-0801 (qd)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ORMD-0801 (bid)
Description: Dose 2 = ORMD-0801 (bid)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ORMD-0801 (tid)
Description: Dose 3 = ORMD-0801 (tid)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: fish oil placebo
Study: NCT01837511

Intervention type: OTHER
Intervention: Data acquisition and analysis
Description: Tumor tissue samples submitted with a Patient and Tumor-Sample Characteristics. Form containing previously collected specific clinical data of patients with pathologically proven stage I, II and III NSCLC.
Study: NCT00634803

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: Cognitive behavioral therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: buprenorphine/naloxone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: buprenorphine/naloxone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: buprenorphine/naloxone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Counseling
Description: Didactic, lecture-discussion format to supplement information and advice provided by physicians

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physician Management
Description: Brief physician counseling
Study: NCT03349060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842 100 mg
Description: PF-04965842 100 mg, administered as two tablets to be taken orally once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842 200 mg
Description: PF-04965842 200 mg, administered as two tablets to be taken orally once daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, administered as two tablets to be taken orally once daily for 12 weeks
Study: NCT01770769

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemi - arthroplasty
Description: modular hemiarthroplasty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: internal fixation
Description: Two cancellous parallel screws - internal fixation of the femoral neck fracture
Study: NCT04405492

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Taking blood samples (capillary and venous), saliva sampling and nasopharyngeal sampling.
Description: After inclusion, demographic and medical data will be collected. Evaluated point-of-care devices will be tested immediately. Blood samples (capillary and venous), salivary sample and nasopharyngeal swab will be taken. Clinical samples will be stored in a dedicated biobank. Other SARS-CoV-2 diagnostic tests will be evaluated in the laboratory on the different clinical samples retrieved from the biobank.~For all antigenic, molecular and serological tests evaluated, the reference method will be real-time RT-PCR as well as the result of medical imaging carried out as part of patient care.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Taking blood samples (capillary and venous), saliva sampling and nasopharyngeal sampling.
Description: After inclusion, demographic and medical data will be collected. Point-of-care devices will be tested immediately. Blood samples (capillary and venous), salivary sample and nasopharyngeal swab will be taken (D0). A follow-up at D15, M1, M3, M6, M9 will be done. At each visit, participants will be asked information about their health status and their contacts with COVID-19 patients. Blood samples (capillary and venous), salivary sample and nasopharyngeal swab will be taken. Point-of-care devices will be tested during the visit.~Cinical samples will be stored in a dedicated biobank. Other SARS-CoV-2 diagnostic tests will be evaluated in the laboratory on the different samples retrieved from the biobank.~For all antigenic, molecular and serological tests evaluated, the reference method will be real-time RT-PCR as well as the result of medical imaging carried out as part of patient care.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capillary and salivary sampling
Description: Two rapid tests (NG Biotech) allowing anti-SRAS-CoV-2 antibodies detection from a fingerpick blood sample and antigen detection from a salivary sample will be provided in 3 pharmacies of Ile de France. The inclusion of lay persons will be carried out in pharmacies by investigators of the recruiting centers (Bacteriology and Virology departments). After inclusion, one of the tests will be given to the participant for self-testing. After performing the test, the participant will complete a questionnaire to give a feedback on the test usability and the result obtained.
Study: NCT01288677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC649128
Description: Escalated doses
Study: NCT01002989

Intervention type: DEVICE
Intervention: Doppler Ankle-Brachial Index measurement
Description: Measurement of the Ankle-Brachial Index by Doppler.

Intervention type: DEVICE
Intervention: WatchBP Office Ankle-Brachial Index measurement.
Description: Measurement of Ankle-Brachial Index by WatchBP Office device.
Study: NCT02920502

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arm 2: cholecalciferol 50,000 IU
Description: One time dose of cholecalciferol 50,000 IU

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arm 3: cholecalciferol 100,000 IU
Description: One time dose of cholecalciferol 100,000 IU

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arm 4: cholecalciferol 200,000 IU
Description: One time dose of cholecalciferol 200,000 IU

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Arm 1: Placebo
Description: One time dose of Placebo
Study: NCT01072773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: 1.3 mg/m\^2, by IV on days 1, 8 and 15 every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 300 mg/m\^2, orally, on days 1, 8, 15 \& 22 every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 40 mg, orally, on days 1, 8, 15 \& 22 every 28 days
Study: NCT02588794

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CytoSorb 300 ml device (3804606CE01)
Description: additional cytokine adsorber
Study: NCT04005430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Episcleral Dexamethasone
Description: Sequestered Transscleral, Controlled-Release Dexamethasone
Study: NCT04455087

Intervention type: OTHER
Intervention: sensitization
Description: sensitization of doctor to decrease the prescription of abuse exams
Study: NCT00961571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib and capecitabine
Description: Sunitinib 37.5 mg po once daily Capecitabine 1000 mg po twice daily
Study: NCT02044120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: niraparib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: niraparib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: niraparib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Study: NCT04236492

Intervention type: PROCEDURE
Intervention: Fresh osteochondral allografting
Description: Transplantation of a fresh osteochondral allograft in the knee
Study: NCT00497523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate/Salbutamol combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol
Study: NCT04276961

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture will be given for a total of 12 session over 4 weeks. Acupuncture at acupoints Tianshu (ST25), Shangjuxu (ST37), Zusanli (ST36), and Neiguan (PC6) bilaterally will be given.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture will be given for a total of 12 session over 4 weeks. Acupuncture at acupoints Tianshu (ST25), Shangjuxu (ST37), Zusanli (ST36), and Neiguan (PC6) bilaterally will be given.
Study: NCT01812460

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention-training-group
Description: As descriped in Arm Description
Study: NCT02940262

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68 Gozetotide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET imaging
Study: NCT03944668

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 36 sessions of comprehensive cardiac rehabilitation over 12 weeks
Study: NCT03548961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: FOLFOX regimen will be administered for 6 cycles. Each cycle is 14 days followed by restaging, local surgery and concurrent chemo radiation therapy
Study: NCT05553990

Intervention type: OTHER
Intervention: intestinal flora disturbance
Description: To observe the clinical prognosis of stroke patients complicated with tumor after enterobacterial disorder
Study: NCT01846364

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diindolylmethane (DIM)
Description: 300 mg of Bioresponse DIM (100mg/day of active DIM) a day for 30 days
Study: NCT00380133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB681323
Description: 5 mg and 2.5 mg tablets - The tablets will be round (9.0 mm in diameter) and white and provided in labelled bottles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: 5 mg size DB AA capsule shell (Swedish orange) with a powder backfill (lactose Anhydrous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets matched to SB681323 or prednisolone
Study: NCT04084418

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Diet
Description: Participants will be provided with a two-week menu to be consumed 3 times for each intervention, for a total of 6 weeks per intervention. For the Control diet, the diet will provide 50% of energy from CHO, 15% from protein, and 35% from lipids. Menu will be adapted to the participant's food preferences and usual caloric intake by a dietitian. Participants will be asked to limit their alcohol intake in both interventions. During this phase, participants will also have to wear a pedometer and use the Pezio: Achieve the Guidelines! mobile application to help the research assistant track their daily steps remotely.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Diet
Description: Participants will be provided with a two-week menu to be consumed 3 times for each intervention, for a total of 6 weeks per intervention. For the Control diet, the diet will provide 50% of energy from CHO, 15% from protein, and 35% from lipids. Menu will be adapted to the participant's food preferences and usual caloric intake by a dietitian. Participants will be asked to limit their alcohol intake in both interventions. During this phase, participants will also have to wear a pedometer and use the Pezio: Achieve the Guidelines! mobile application to help the research assistant track their daily steps remotely.
Study: NCT03797768

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural-FCHV Visit
Description: Female Community Health Volunteer will visit selected households on average 3 times a year for providing health promotion messages on improving lung health status and avoiding risk factors to COPD.
Study: NCT04084418

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VLCHF Diet
Description: Participants will be provided with a two-week menu to be consumed 3 times for each intervention, for a total of 6 weeks per intervention. For the Experimental diet, the diet will provide 10% of energy from CHO, 15% from protein, and 75% from lipids. During the Experimental diet, participants will be provided with a multivitamin to reduce risk of deficiencies due to restrictions on fruits and grain products. Menu will be adapted to the participant's food preferences and usual caloric intake by a dietitian. Participants will be asked to limit their alcohol intake in both interventions. During this phase, participants will also have to wear a pedometer and use the Pezio: Achieve the Guidelines! mobile application to help the research assistant track their daily steps remotely.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VLCHF Diet
Description: Participants will be provided with a two-week menu to be consumed 3 times for each intervention, for a total of 6 weeks per intervention. For the Experimental diet, the diet will provide 10% of energy from CHO, 15% from protein, and 75% from lipids. During the Experimental diet, participants will be provided with a multivitamin to reduce risk of deficiencies due to restrictions on fruits and grain products. Menu will be adapted to the participant's food preferences and usual caloric intake by a dietitian. Participants will be asked to limit their alcohol intake in both interventions. During this phase, participants will also have to wear a pedometer and use the Pezio: Achieve the Guidelines! mobile application to help the research assistant track their daily steps remotely.
Study: NCT03809754

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention under OCT
Description: After randomization, subjects receive primary PCI under the guiding of OCT

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Percutaneous Coronary Intervention under Angiography
Description: After randomization, subjects receive primary PCI under the guiding of angiography
Study: NCT01372995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteral Vitamin D3 50,000 IU
Description: Enteral Vitamin D3 50,000IU x 5 days (total dose 250,000IU)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteral Vitamin D3 100,000IU
Description: Enteral Vitamin D3 100,000IU over 5 days (total 500,000IU)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inactive substance
Description: Inactive substance given enterally for 5 days.
Study: NCT04696822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine Nasal Product, 1.6 mg
Description: Single dose Nasal powder spray without allergen challenge

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine nasal product, 1.6 mg + allergen
Description: Single dose Nasal powder spray with allergen challenge

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine Injection 0.3 mg
Description: Intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine Nasal Product, 3.2 mg
Description: Twice dose Nasal powder spray without allergen challenge

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine Nasal Product, 3.2 mg + allergen
Description: Twice dose Nasal powder spray with allergen challenge
Study: NCT01580670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-650
Description: TA-650 will be intravenously infused at 5 mg/kg as an induction regimen at Week 0, 2, 6. For subjects who meet the responder criteria, TA-650 will be administered at 8-week intervals thereafter until week 46. If the criteria for a dosage escalation are met, TA-650 will be administered at a dosage of 10 mg/kg.
Study: NCT04183296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Anesthesia was induced with TCI of propofol (Ce of 4.0-4.5 μg/ml) and remifentanil (Ce of 4.0 ng/ml). Anesthesia was maintained with TCI of propofol and remifentanil. Anesthesia depth was adjusted to maintain a PSI of 25-50.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane
Description: Anesthesia was induced with an intravenous bolus of propofol 1.5-2 mg/kg and TCI of remifentanil (effect-site concentration \[Ce\] of 4.0 ng/ml). Anesthesia was maintained with sevoflurane (0.8-1 age-adjusted minimum alveolar concentration) and TCI of remifentanil
Study: NCT01653821

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carotid body excision
Study: NCT03971136

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: pulmonary ultrasound
Description: The subjects will have an ultrasound on admission and on day 1, 2 and 3
Study: NCT01576679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cathflo (Alteplase)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study: NCT02764762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab injection for subcutaneous use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate oral tablets.
Study: NCT01231451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMPA
Description: All subjects will take DMPA
Study: NCT04181892

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronally advanced flap + connective tissue graft
Description: connective tissue graft covered by a coronally advanced flap with connective tissue graft apical of the cementoenamel junction level
Study: NCT00602641

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: Given PO
Study: NCT01097538

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Body-weight supported treadmill training
Description: Patients will undergo training using the Woodway Loco-system which consists of a treadmill with an overhead pulley system connected to a support harness. BWSTT allows patients with limited mobility to safely walk upright on a treadmill with a portion of their body weight counter balanced. Three trainers will be required to assist with the BWSTT program. Two trainers will be positioned at the lower limbs to manually guide the participant through a proper gait motion and provided lower limb control. A third trainer will stand behind the participant to provide trunk support and assist with weight shifting.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Total body recumbent stepper training
Description: Patients will train using the Nustep T4 (TRS 4000) which is a recumbent cross trainer that provides a full body workout in a seated position. The Nustep trainer allows patients to achieve a natural stepping motion against graded loads with bilateral reciprocal movement of the arms. Recumbent training is safe and easily accessible for patients of all ability levels with a swivel chair to aid in patient transfers. Foot straps, leg stabilizers and hand stabilizers may be used for added control and proper body alignment.
Study: NCT02043210

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment as Usual
Description: Treatment normally offered at this clinic which could include individual or group substance use counseling sessions one time per week lasting one hour each time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT4CBT plus Standard treatment as usual
Description: Subjects work with a computerized program in Spanish that teaches skills for stopping substance use and increasing coping skills. Computerized sessions are one time per week and last about one hour per session. Plus Standard treatment as usual
Study: NCT02468427

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hands-on teaching
Description: Training session of 30 minutes duration with every proband performing a vacuum extraction on a pelvic training model.
Study: NCT00991133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine incorporated into a 5-drug regimen
Description: Clofarabine (IV) 40mg/m2 into an intensive chemotherapy regimen of etoposide, cyclophosphamide, PEG-asparaginas, and vincristine
Study: NCT00083122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin/flavopiridol
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin/flavopiridol
Description: Given IV
Study: NCT01889771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: nicoderm patches are distributed in two different supplies through a telephone quitline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: nicoderm patches are distributed in two different supplies through a telephone quitline
Study: NCT01552642

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: face-to-face meetings and access to a website
Description: The intervention group will have 6 weekly face-to-face meetings and will have access to a website.
Study: NCT04181892

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Coronally advanced flap + connective tissue graft
Description: connective tissue graft covered by a coronally advanced flap with connective tissue graft apical of the cementoenamel junction level
Study: NCT01977755

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: danegaptide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: danegaptide
Study: NCT02468427

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Frontal teaching
Description: Training session of 30 minutes duration consisting of a video which demonstrates how to perform a vacuum extraction on a pelvic training model.